Effects of p38 MAPK inhibitor on the rat pain behavior and proinflammatory cytokines in a metastatic bone cancer pain model

By Tang Cuiju  

The Chinese-German Journal of Clinical Oncology, Vol. 7, Iss. 3, 2008-03 ,pp. : 154-158

Springer Publishing Company

Access to resources Recommend Favorite

Receptor activator of nuclear factor-κB ligand (RANKL)/RANK/osteoprotegerin system in bone and other tissues (Review)

By    

Molecular Medicine Reports, Vol. 11, Iss. 5, 2015-01 ,pp. : 3212-3218

Spandidos Publications

Access to resources Recommend Favorite

Bone metastases in gastric cancer follow a RANKL-independent mechanism

By                      

Oncology Reports, Vol. 29, Iss. 4, 2013-01 ,pp. : 1453-1458

Spandidos Publications

Access to resources Recommend Favorite

Abnormal bone remodeling process is due to an imbalance in the receptor activator of nuclear factor-κB ligand (RANKL)/osteoprotegerin (OPG) axis in patients with solid tumors metastatic to the skeleton

By Mountzios Giannis   Dimopoulos Meletios-Athanassios   Bamias Aristotelis   Papadopoulos George   Kastritis Efstathios   Syrigos Konstantinos   Pavlakis George   Terpos Evangelos  

Acta Oncologica, Vol. 46, Iss. 2, 2007-01 ,pp. : 221-229

Informa Healthcare

Access to resources Recommend Favorite

Hyaluronan synthesis inhibitor supplements the inhibitory effects of zoledronic acid on bone metastasis of lung cancer

By Futamura Naohisa  

Clinical and Experimental Metastasis, Vol. 30, Iss. 5, 2013-06 ,pp. : 595-606

Springer Publishing Company

Access to resources Recommend Favorite